NCT04088318进行中（未招募）2 期
A Phase II Study to Evaluate the Safety and Efficacy of OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 170
- 试验地点
- 32
- 主要终点
- (For Part 1) Proportion of patients who achieve NCI CTCAE v5.0 - Palmar-Plantar Erythrodysesthesia (PPE) grade 0 or 1 OR (for Part 2) The proportion of patients achieving IGA-HFSR grade 0 or 1
研究概览
简要总结
Hand-Foot Skin Reaction (HFSR) is a common adverse event induced by Vascular Endothelial Growth Receptor Inhibitor (VEGFRi) treatment in cancer patients. The main purpose of this study is to evaluate the safety and efficacy of OQL011 compared to vehicle ointment in treating patients with moderate to severe VEGFRi-associated HFSR. This study will also identify an optimal dosage for Phase III study and explore the pharmacokinetics profile of OQL011 in HFSR patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Supportive Care
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient must be age ≥ 18 years.
- •Patient must have a confirmed cancer diagnosis for which VEGFRi treatment is indicated, and must be currently under VEGFRi-based anti-cancer therapy with stable dosage for ≥ 1 week. This treatment may be VEGFRi monotherapy or VEGFRi-based combination therapy, so long as it does not include prohibited therapies.
- •Patient must have shown signs of HFSR that meet (for Part 1) the NCI CTCAE v5.0 - PPE grade 2 or higher OR (for Part 2) IGA-HFSR criteria of grade 3 or higher.
- •Patient on pain medications is allowed provided they have been on stable dosage in the past 1 week and is going to continue at the same dosage.
- •Patient is able to use topical medications and complete questionnaires reliably.
- •Eastern Cooperative Oncology Group (ECOG) performance score ≤
- •Patient must have the ability to understand and the willingness to sign a written informed consent prior to study entry.
排除标准
- •Patient with unresolved hand or foot skin disorders (NCI CTCAE v5.0 grade 2 or higher) due to other medications within 4 weeks prior to study entry.
- •Patient who is using other topical medications in the hands or feet area and cannot stop such usage >7 days ahead of randomization.
- •Patient who is using other concurrent cancer medications, such as capecitabine, pegylated liposomal doxorubicin, 5-fluorouracil, dabrafenib, vemurafenib, doxorubicin, docetaxel, cytarabine, ramucirumab and bevacizumab, which may result in hand-foot syndrome (HFS).
- •Patient who is under uncontrolled intercurrent illness including, but not limited to, inadequately controlled nausea, vomiting, diarrhea or other conditions which may contribute to hypovolemia, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, recent myocardial infarction, uncontrolled hypotension or hypertension, cardiac arrhythmia, or psychiatric illness and social situations that would limit compliance with study requirements.
- •Patient who has contraindication with the active compound, including severe anemia, increased intracranial pressure, known hypersensitivity.
- •Patient who has other skin disorders that will affect the efficacy evaluation on hands and feet area, including but not limited to, tinea of feet and hands, hand/foot eczema, palmoplantar pustulosis, palmoplantar keratosis, acrodermatitis continua etc.
- •Patient who used phosphodiesterase type 5 (PDE5) inhibitors such as sildenafil, vardenafil, and tadalafil within past 7 days.
- •Patient with significantly abnormal lab test:
- •Inadequate hematologic function as indicated by:
- •Absolute neutrophil counts (ANC) ≤ 1,000 /mm^3
- •Hemoglobin (Hgb) ≤ 8.0 g/dL
- •Platelet count ≤ 75,000 /mm^3
- •PT or PTT > 1.5 x ULN (if patients on anticoagulants: PT INR > 3.5 x ULN)
- •Inadequate renal and liver function as indicated by:
- •Albumin < 2.8 g/dL
- •Total bilirubin ≥ 1.5 x ULN (or ≥ 2.5 x ULN for patients with Gilbert's syndrome)
- •Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase ≥ 3 x ULN (or ≥ 5 x ULN for patients with liver cancer)
- •Creatinine > 2.0 x ULN.
- •Pregnant or nursing women.
- •Women of childbearing potential who are unwilling to comply with contraceptive requirements. Highly effective contraception which include two forms of birth control method (i.e., a hormonal method plus a barrier method) is advised for at least 2 weeks prior to study treatment and during study participation.
研究组 & 干预措施
OQL011 Dose I
Experimental
OQL011, Dose I, ointment, to be applied topically, three times a day, for up to six weeks (in Part 1) or four weeks (in Part 2)
干预措施: OQL011 (Drug)
OQL011 Dose II
Experimental
OQL011, Dose II, ointment, to be applied topically, three times a day, for up to six weeks (in Part 1) or four weeks (in Part 2)
干预措施: OQL011 (Drug)
OQL011 Dose III
Experimental
OQL011, Dose III, ointment, to be applied topically, three times a day, for up to six weeks (in Part 1) or four weeks (in Part 2)
干预措施: OQL011 (Drug)
Vehicle Ointment
Other
Vehicle ointment, to be applied topically, three times a day, for up to six weeks (in Part 1) or four weeks (in Part 2)
干预措施: Vehicle Ointment (Drug)
结局指标
主要结局
(For Part 1) Proportion of patients who achieve NCI CTCAE v5.0 - Palmar-Plantar Erythrodysesthesia (PPE) grade 0 or 1 OR (for Part 2) The proportion of patients achieving IGA-HFSR grade 0 or 1
时间窗: 3 weeks (Part 1) OR 2 weeks (Part 2)
次要结局
- (For Part 1) Proportion of patients who achieve NCI CTCAE v5.0 - PPE grade 0 or 1(6 weeks)
- (For Part 2) Change from baseline in NCI CTCAE v5.0 - PPE grade(2 weeks and 4 weeks)
- (For Part 2) The exposure-response relationship of different dose level OQL011(4 weeks)
- Change from baseline in HF-QoL (Hand-Foot Skin Reaction and Quality of Life) Questionnaire total score(3 weeks and 6 weeks (Part 1) OR 2 weeks and 4 weeks (Part 2))
- Safety assessment by type, incidence and intensity of adverse events(6 weeks (Part 1) and 4 weeks (Part 2))
- (For Part 1) Change from baseline in patient reported pain using VAS (Visual Analog Scale)(3 weeks and 6 weeks)
- (For Part 1) Proportion of patients who have improvement in HFSR severity and achieve clear (0) or almost clear (1) as measured by IGA-c (Centrally-assessed Investigator's Global Assessment) scale(3 weeks and 6 weeks)
- (For Part 2) Change from baseline in patient reported pain using NPRS (Numerical Pain Rating Scale)(2 weeks and 4 weeks)
- Plasma concentration of active compound and its derivatives(1 day)
- (For Part 1) Proportion of patients who have improvement in HFSR severity and achieve clear (0) or almost clear (1) as measured by IGA-i (Investigator-assessed Investigator's Global Assessment) scale(3 weeks and 6 weeks)
- (For Part 2) Proportion of patients achieving IGA-HFSR grade 0 or 1(4 weeks)
- (For Part 2) Proportion of patients achieving at least two-grade improvement in IGA-HFSR(2 weeks and 4 weeks)
研究者
研究点 (32)
Loading locations...
相似试验
Unknown
2 期
A Study to Investigate Nicotinic Acid on VEGFR Inhibitor-Associated Hand-Foot Skin ReactionsHand-Foot Skin Reaction (HFSR)NCT04242927First People's Hospital of Hangzhou36
已完成
不适用
Prevention of Hand-foot Skin ReactionHepatocellular CarcinomaNCT04568330Taipei Veterans General Hospital, Taiwan129
已完成
1 期
Safety & Immunogenicity of Enterovirus Type 71 Vaccine in Healthy Adults and Children 6-71monthsHand Foot & Mouth DiseaseNCT04467541International Centre for Diarrhoeal Disease Research, Bangladesh430
Unknown
2 期
Urea Cream Prevention for Capecitabine Associated Hand Foot SyndromeHand-Foot SyndromeNCT05348278Mahidol University214
终止
1 期
Eniluracil Hand Foot SyndromeColon CancerBreast CancerNCT00827580West Virginia University3